
Metaplastic Clinical Trials
ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical trials and studies of human participants conducted around the world. Below is a link for you to search and educate yourself to any possible treatment options for metaplastic breast cancer for you to address with your oncologist. https://www.nih.gov/health-information/nih-clinical-research-trials-you/finding-trials-clinicaltrialsgov
Clinical Trials for Metaplastic Breast Cancer
Approval Dates Location Type Phase Criteria/Contacts Approval Dates:
6/2016 to 12/2020 Location:
Type:
ARQ 751 in Solid Tumors with AKT1, 2,
3 Genetic Alterations, Activating PI3K Mutations, PTEN-null,
or Other Known Actionable PTEN Mutations Phase:
Phase 1 Criteria/Contacts:
Link Approval Dates:
1/13/17 to 8/31/2020 Location:
LOCATIONS Type:
DART: DUAL ANTI-CLA-4 AND ANTI- PD1 BLOCKADE IN RARE TUMORS-
INTERVENTIONAL Phase:
Criteria/Contacts:
Link
Link
Link
Link Approval Dates:
11/2015 to 11/2020 Location:
UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER-
HOUSTON, TX Type:
ARTEMIS TRIAL-
INTERVENTIONAL Phase:
Criteria/Contacts:
Link
Link Approval Dates:
10/4/2016 to 3/14/2017 Location:
NYU LANGONE MEDICAL CENTER-
NY, NY Type:
IMMUNOTHERAPY COMBO-
PEMBROLIZUMAB & NABPACLITAXEL Phase:
Phase 2 Criteria/Contacts:
Link Approval Dates:
7/2016 to 8/2019 Location:
HOUSTON METHODIST HOSPITAL
HOUSTON, TX Type:
IMMUNOTHERAPY COMBO-
L-NMMA PLUS DOCETAXEL Phase:
Phase 1B Criteria/Contacts:
Link Approval Dates:
1/2016-1/2019 Location:
UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER-
HOUSTON, TX Type:
TARGETED THERAPY Phase:
Phase 2 Criteria/Contacts:
Link
Clinical Trials for Metaplastic Breast Cancer
Approval Dates | Location | Type | Phase | Criteria/Contacts |
---|---|---|---|---|
Approval Dates: 6/2016 to 12/2020 | Location: | Type: ARQ 751 in Solid Tumors with AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations, PTEN-null, or Other Known Actionable PTEN Mutations | Phase: Phase 1 | Criteria/Contacts: Link |
Approval Dates: 1/13/17 to 8/31/2020 | Location: LOCATIONS | Type: DART: DUAL ANTI-CLA-4 AND ANTI- PD1 BLOCKADE IN RARE TUMORS- INTERVENTIONAL | Phase: | Criteria/Contacts: Link Link Link Link |
Approval Dates: 11/2015 to 11/2020 | Location: UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER- HOUSTON, TX | Type: ARTEMIS TRIAL- INTERVENTIONAL | Phase: | Criteria/Contacts: Link Link |
Approval Dates: 10/4/2016 to 3/14/2017 | Location: NYU LANGONE MEDICAL CENTER- NY, NY | Type: IMMUNOTHERAPY COMBO- PEMBROLIZUMAB & NABPACLITAXEL | Phase: Phase 2 | Criteria/Contacts: Link |
Approval Dates: 7/2016 to 8/2019 | Location: HOUSTON METHODIST HOSPITAL HOUSTON, TX | Type: IMMUNOTHERAPY COMBO- L-NMMA PLUS DOCETAXEL | Phase: Phase 1B | Criteria/Contacts: Link |
Approval Dates: 1/2016-1/2019 | Location: UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER- HOUSTON, TX | Type: TARGETED THERAPY | Phase: Phase 2 | Criteria/Contacts: Link |